Ποια είναι η τιμή για CohBar, Inc. (CWBR)

Η τιμή για CohBar, Inc. (CWBR) είναι $0.41

Ποια είναι η κεφαλαιοποίηση αγοράς για CohBar, Inc. (CWBR)

Η κεφαλαιοποίηση αγοράς για CohBar, Inc. (CWBR) είναι $1.08M

CohBar, Inc. (CWBR) Τιμή και Κεφαλαιοποίηση Αγοράς

CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.

Η τιμή για CWBR	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$2,078,407 $1.08M	NVDA	$5.452T	+506,928,540.64%
$1,711,724 $1.08M	AAPL	$4.490T	+417,493,487.91%
$1,586,828 $1.08M	GOOG	$4.162T	+387,031,177.16%
$1,401,527 $1.08M	MSFT	$3.676T	+341,835,646.28%
$1,080,037 $1.08M	AMZN	$2.833T	+263,423,467.36%

Η τιμή για CWBR

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$2,078,407 $1.08M